echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The gold digging journey of biomedical industry is on its way

    The gold digging journey of biomedical industry is on its way

    • Last Update: 2015-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: at present, countries and organizations have different definitions and scopes of the biotechnology industry, and even different people's opinions are often quite different Global M & a boom in biomedical industry continues to heat up Biotechnology is a comprehensive technology based on the theory of modern life science, which makes use of the components of organism and its cells, subcellular and molecule, combines with engineering, informatics and other means to carry out research and manufacture products, or to transform animals, plants, microorganisms and so on, and make them have the desired quality and characteristics, so as to provide goods and services for the society Department Biopharmaceutical industry consists of biotechnology industry and pharmaceutical industry The dual favor of the government and capital has injected development vitality into the biomedical industry known as the "gold industry of the 21st century", and the gold digging trip is on the way According to incomplete statistics, since 2012, there are more than 600 kinds of drugs in China, namely the so-called "cliff period" By 2020, about 259 billion US dollars worth of drugs will face failure, which provides an excellent development opportunity for the Chinese market dominated by Western drug imitation In September 2014, Guangzhou Pharmaceutical Group announced that its domestic "Viagra" was officially approved, while the Viagra (commonly known as "Viagra") produced by Pfizer pharmaceutical group of the United States in China expired in May 2014 In the capital market, biomedical sector is called "gold mine" by investors According to Qingke data, in 2012, there were 188 PE / VC cases invested in biotechnology / health care in China, with an investment of US $1.898 billion, totaling about RMB 11.8 billion In addition, the global M & a boom in the biomedical industry continues to heat up According to the statistics of 2014-2018 China biomedical industry research report released by China report hall, as of August 2014, the total announced M & A transactions in the global pharmaceutical, biotechnology and medical product industries reached 354.7 billion US dollars, a record high in the same period, with a year-on-year growth rate of more than five times According to the research, the development opportunity of industrial gold has come Local biomedical enterprises should recognize the current situation of international and domestic industrial development, and find their own development mode, so as to truly walk out of the road of pharmaceutical power.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.